Mutations in the pantothenate kinase 2 (PANK2) gene have been identified in patients with neurodegeneration with brain iron accumulation (NBIA; formerly Hallervorden-Spatz disease). However, the mechanisms by which these mutations cause neurodegeneration are unclear, especially given the existence of multiple pantothenate kinase genes in humans and multiple PanK2 transcripts with potentially different subcellular localizations. We demonstrate that PanK2 protein is localized to mitochondria of neurons in human brain, distinguishing it from other pantothenate kinases that do not possess mitochondrial-targeting sequences. PanK2 protein translated from the most 5Ј start site is sequentially cleaved at two sites by the mitochondrial processing peptidase, generating a long-lived 48 kDa mature protein identical to that found in human brain extracts. The mature protein catalyzes the initial step in coenzyme A (CoA) synthesis but displays feedback inhibition in response to species of acyl CoA rather than CoA itself. Some, but not all disease-associated point mutations result in significantly reduced catalytic activity. The most common mutation, G521R, results in marked instability of the intermediate PanK2 isoform and reduced production of the mature isoform. These results suggest that NBIA is caused by altered neuronal mitochondrial lipid metabolism caused by mutations disrupting PanK2 protein levels and catalytic activity.
Introduction
Neurodegeneration with brain iron accumulation (NBIA), formerly known as Hallervorden-Spatz disease, often begins within the first few years of life and leads to progressive impairment of movement, speech, and cognition (Dooling et al., 1974; Swaiman, 1991) . Iron accumulation in the globus pallidus can be visualized by magnetic resonance imaging (MRI), often in a characteristic pattern referred to as the "eye-of-the-tiger" sign (Hayflick et al., 2003) . Hypoprebetalipoproteinemia, acanthocytosis, and pigmentary retinopathy are sometimes associated with neurological impairment in NBIA, referred to as HARP syndrome when all three additional features are present (Higgins et al., 1992; Orrell et al., 1995) . No therapy currently exists to stop or reverse progression of the disease.
Postmortem examination of NBIA brains reveals a number of pathological features (Halliday, 1995) . Histochemical stains demonstrate iron accumulation primarily in the basal ganglia. There is also deposition of proteinaceous material in axonal inclusions termed spheroids. These inclusions have been shown in various case reports to contain ␣-synuclein (␣-syn) and neurofilament proteins (Malandrini et al., 1995; Wakabayashi et al., 1999 Wakabayashi et al., , 2000 Galvin et al., 2000; Neumann et al., 2000; Saito et al., 2000) . Many cases contain ␣-syn-positive Lewy bodies in addition to axonal spheroids, strengthening the link between NBIA and Parkinson's disease at the pathological level. Neurofibrillary tangles containing the microtubule-associated protein tau have also been observed in the cortex (Wakabayashi et al., 2000) . Neuronal loss and gliosis accompany these pathological changes and can be widespread, involving cortical regions as well as basal ganglia and brainstem areas.
The phenotypic features of NBIA suggest that understanding its pathogenesis may yield insight into disease mechanisms underlying inclusion formation, iron accumulation, and oxidative stress that are common to other more prevalent neurodegenerative disorders such as Alzheimer's and Parkinson's disease. The recent identification of pantothenate kinase 2 (PANK2) gene mutations in NBIA as well as HARP syndrome represents a unique opportunity to better understand the pathogenesis of this neurodegenerative disease (Zhou et al., 2001; Ching et al., 2002; Houlden et al., 2003) . PANK2 is a member of a family of eukaryotic genes encoding pantothenate kinases, which catalyze the phosphorylation of pantothenate (vitamin B5) to yield phosphopantothenate. This process is the first of five enzymatic steps in the biosynthesis of coenzyme A (CoA), a universal acyl carrier used by perhaps as many as 4% of all enzymes (Begley et al., 2001) .
Four putative pantothenate kinase genes have been identified in the human genome. One unique feature of PanK2 may be its mitochondrial localization, predicted by computer sequence analysis and expression of PanK2-GFP fusion proteins in cell lines (Hortnagel et al., 2003) . However, alternatively spliced PanK2 transcripts lacking a mitochondrial targeting sequence have also been isolated from human brain (Hortnagel et al., 2003) .
To investigate the mechanisms by which PanK2 mutations result in neurodegeneration, we generated specific PanK2 antibodies to characterize the cellular and subcellular localization of PanK2 in human brain. We also used overexpression in 293 cells to characterize the mitochondrial targeting, proteolytic processing, half-life, and catalytic properties of normal PanK2 as well as PanK2 proteins containing NBIA-associated point mutations.
Materials and Methods
Materials. Chemicals, including CoA synthesis intermediates and CoA esters, were obtained from Sigma (St. Louis, MO) unless otherwise indicated. Secondary antibodies were obtained from Jackson ImmunoResearch (West Grove, PA).
Plasmids. The full-length human PanK2 coding sequence was amplified by PCR from human brain Marothon-Ready cDNA (BD Biosciences, Palo Alto, CA). The forward primer AAGAATTCACCATGAGGAG-GCTCGGGCCCTTC contained an EcoRI restriction site 5Ј to the ATG start site, and the reverse primer TATCTAGATGATCACGGGATCTTCAACAG contained an XbaI site downstream of the stop codon. The coding sequence was also amplified using the same forward primer in combination with a reverse primer TATCTAGACGGGATCTTCAACAGCTCAAG that lacked a stop codon to enable fusion of a myc epitope tag and poly-histidine tag to the C terminus of PanK2. PCR products were subcloned into the pGEM-T vector and sequenced completely. The EcoRI and XbaI digested inserts were then ligated into either pcDNA 3.1 or pcDNA 3.1 myc-his. Point mutations were generated in the pcDNA 3.1 PanK2-myc-his plasmid according to the Quickchange Site-Directed Mutagenesis protocol (Stratagene, La Jolla, CA), using the following oligonucleotides (sequences shown for sense strand): CGCGCCCATGGGGCGCCACGGCA for E134G, GGTTTGGACTG-GATATCGTTGGAACTCTGGTCAAG for G219V, TGAACCCAAAGA-CATCGCTGCTGAAGAAGAAGAGG for T234A, GGGCTGTGGCT-TCAAACTTTGGAAACATGATGAGC for S471N, CCAGGTGGTATT-TGTTAGAAATTTCTTGAGAATTAATACGATCGC for G521R, and TG-GAAATTTCTTGAGAATTAATATGATCGCCATGCGGCTTTTG for T528M. For production of recombinant human PanK2 in Escherichia coli, PanK2 coding sequence beginning at a predicted alternative CTG start site (Zhou et al., 2001 ) was inserted into pET-30a vector (Novagen, Madison, WI) by cloning a BamHI-EcoRI fragment from pMJ2 (a gift from Susan Hayflick, Oregon Health and Science University, Portland, OR) into BamHI-EcoRI digested pET30a.
Production of bacterial recombinant PanK2 protein. Host BL21(DE3) E. coli was transformed with pET30a-PANK2 expression plasmid and incubated overnight after plating. The next morning, transformed colonies were resuspended from the plate in two washes of 5-10 ml of Luria broth (LB) and inoculated into a flask with 200 ml of LB with kanamycin. When the culture reached an OD 600 of 0.6 (ϳ2 h), isopropyl-␤-D-thiogalactopyranoside was added to 0.4 mM, and the culture was incubated for an additional 2 h. Inclusion bodies containing insoluble PanK2 protein were purified as described previously (Nagai and Thogersen, 1987) , and protein was solubilized in 10 mM Tris buffer, pH 8.0, containing 6 M urea, 5 mM EDTA, and 1% ␤-mercaptoethanol.
PanK2 polyclonal antibody production. Rabbit polyclonal antibodies to PanK2 were produced using two PanK2 peptides lacking significant homology to PanK1, PanK3, and PanK4. PanK2 549 was generated from the peptide CEQAAGDPEGRRQEPLRRRAS, corresponding to amino acids 9 -28 of mature human PanK2. PanK2 550 was generated from the peptide CENPADSEKCQKLPFDLKNP, corresponding to amino acids 224 -243 of mature human PanK2. Peptides were conjugated to maleimideactivated KLH and BSA protein (Pierce, Rockford, IL) according to the manufacturer's instructions, and equal quantities of the peptide conjugates were injected subcutaneously and intramuscularly every 3 weeks for a total of four injections. Injection of antigen and collection of antisera were performed by Covance Research Products (Denver, PA). Peptide antisera were affinity purified using bacterial recombinant PanK2 protein coupled to Affi-Gel 10 (Bio-Rad, Hercules, CA) according to the manufacturer's instructions.
PanK2 monoclonal antibody production. Monoclonal antibodies were generated against bacterial recombinant human PanK2. Mice received initial subcutaneous injections of 100 g of protein emulsified in Freund's complete adjuvant, followed by additional subcutaneous injections of 25 g of protein emulsified in Freund's incomplete adjuvant on days 21 and 42, and an intraperitoneal injection of 25 g of protein in PBS on day 109. On day 112, the spleen was removed, and the lymphocytes were fused to myeloma cells (line Sp2/0-Ag14) using polyethylene glycol 1500 (Tu et al., 1998) . Ascites fluid was produced from monoclonal cell line 25.1, and IgG was purified using Hitrap Protein G Sepharose column (Amersham Biosciences, Piscataway, NJ).
Human brain extraction and Western blot analysis. Protein was extracted from various brain regions of histopathologically normal control brains obtained from the Center for Neurodegenerative Disease Research (CNDR) brain bank at the University of Pennsylvania. Brain tissue samples of 0.15 g were homogenized in 0.3 ml of radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) that contained a mixture of protease inhibitors (PI) (1 g/ml each of pepstatin-A, leupeptin, N-␣-tosyl-L-phenylalanine chloromethyl ketone, N-tosyl-L-lysine chloromethyl ketone, soybean trypsin inhibitor, and EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF), and O-phenanthroline. Homogenates were centrifuged at 100,000 ϫ g to remove insoluble material. For Western blot analysis, samples were separated on SDS-PAGE and transferred to nitrocellulose as described previously (Kotzbauer et al., 2004) . SDS-PAGE was performed in Criterion precast 10% polyacrylamide gels. Antibody concentrations used for Western blot analysis were 1:5000 for affinity-purified PanK2 549, 1:2500 for affinity-purified PanK2 550, and 1:5000 for protein G-purified PanK2 25.1. Blocking buffer was 5% milk in TTBS (50 mM Tris, pH 7.5, 150 mM NaCl, and 0.01% Tween 20) for PanK2 549 and 550. For PanK2 25.1, blocking buffer was 4% bovine serum albumin in TTBS.
Immunohistochemistry. Immunohistochemistry with antibodies to human PanK2 was performed on histopathologically normal control brain tissue from the CNDR brain bank, which was formalin-fixed, paraffin-embedded, and processed for immunohistochemistry as described previously (Duda et al., 2000) . Antibodies used for immunohistochemistry were diluted in blocking buffer [2% fetal bovine serum (FBS) in 0.1 M Tris buffer] (1:250 for PanK2 549 and 25.1 and 1:125 for PanK2 550).
Immunoelectron microscopy. For immunoelectron microscopy, selected brain sections were labeled with antibody PanK2 549 (1:100) and sequentially incubated with a biotinylated goat anti-rabbit antibody and HRP-conjugated streptavidin. After chromogen reaction with diaminobenzidine (DAB)-containing medium, reaction products were enhanced by the silver methenamine method as described previously (Rodriguez et al., 1984) . Sections were postfixed with 1.5% glutaraldehyde and 1% osmium tetraoxide, dehydrated in graded ethanols, and embedded in Epon. Ultrathin sections were prepared and examined by electron microscopy (EM).
Cell Medium was removed, and cells were washed with 10 ml of PBS and gently scraped into 2 ml of PBS per plate. Cells were centrifuged at 1500 ϫ g for 5 min, and the cell pellet was resuspended in TS buffer (0.1 M Tris, pH 8.0, 0.25 M sucrose, 1.5 mM DTT, 10 mM NaF, and PI mixture). Cells were passed through a 25 gauge needle five times and homogenized using a Dounce B homogenizer. Nuclei were pelleted at 1000 ϫ g. The supernatant was removed and centrifuged at 12,000 ϫ g. A Dounce A homogenizer was used to resuspend the mitochondrial pellet in TS buffer.
Purification of recombinant PanK2 protein. Mitochondrial fractions from 293 cells were diluted in four volumes of NiNTA binding buffer (NBB) (50 mM Tris, pH 8.0, 500 mM NaCl, 0.1% Triton X-100, 10 mM NaF, and PI) containing 25 mM imidazole. The mitochondrial suspension was sonicated and centrifuged at 12,000 ϫ g for 10 min. The supernatant was added to NiNTA agarose (Qiagen, Valencia, CA) equilibrated in NBB with 20 mM imidazole and incubated for 30 min with rocking in a disposable column. After allowing extract containing unbound protein to flow through the resin bed, the column was washed with 10 volumes of NBB containing 20 mM imidazole and then eluted with two volumes of NBB containing 250 mM imidazole.
PanK2 enzymatic assay. Catalytic activity of recombinant PanK2 protein was determined based on an assay described for PanK1 (Rock et al., 2000 (Rock et al., , 2002 . Protein preparations were assayed in a mixture containing 45.5 M D-[1-
14 C]pantothenate (55 mCi/mmol; American Radiolabeled Chemicals, St. Louis, MO), 2.5 mM ATP, 2.5 mM MgCl, 0.5 mg/ml BSA, 1.5 mM DTT, and 0.1 M Tris, pH 7.5, in a total volume of 40 l. The mixture was incubated for 10 min at 37°C and then applied to a Whatman (Maidstone, UK) DE81 ion-exchange filter disc. The filter discs were washed three times in 95% ethanol with 1% acetic acid to remove pantothenate substrate. Filter bound 4Ј phosphopantothenate was quantitated by scintillation counting. Background counts were determined by parallel assays performed in the absence of added protein and subtracted from counts obtained for assays of PanK2 protein preparations. Measured enzymatic activity was linear with respect to time and Pank2 protein concentration.
N-terminal sequence analysis of PanK2 intermediate and PanK2 mature. Recombinant PanK2-myc-his protein purified from 293 cells (4 g) was concentrated in a Microcon centrifuge concentrator (Millipore, Billerica, MA) and resolved by SDS-PAGE using a 10% acrylamide gel with the addition of 0.1 mM thioglycolate to the cathode buffer. Protein was transferred to Sequi-Blot polyvinylidene difluoride (PVDF) membrane (BioRad). The membrane was stained with amido black, and bands corresponding to PanK2 intermediate (PanK2 i ) and PanK2 mature (PanK2 m ) were excised. N-terminal amino acid sequencing was performed by the W. M. Keck Facility at Yale University (New Haven, CT).
Ion exchange separation of PanK2 i and PanK2 m . Mitochondrial fractions of QBI 293 cells expressing human PanK2 were diluted in four volumes of SP buffer (50 mM HEPES, pH 7.4, 0.1% Triton X-100, 10 mM NaF, 1.5 mM DTT, and PI mixture) containing 100 mM NaCl and applied to a 1 ml HiTrap SP Sepharose column (Amersham Biosciences) at a flow rate of 0.5 ml/min. The column was washed with SP buffer containing 0.1 M NaCl, and bound protein was eluted with a 20 ml linear gradient of 0.1-1.0 M NaCl in SP buffer. Fractions of 0.5 ml were collected and analyzed by Western blot analysis. Recombinant PanK2 isoforms were concentrated from 0.2 ml of each fraction by immunoprecipitation with PanK2 549 and protein A-Sepharose beads as described above. After washing the beads once with enzymatic assay buffer minus 14 Cpantothenate, 40 l of enzymatic assay mixture was added to protein ASepharose-bound protein from each fraction and incubated for 10 min at 37°C with shaking. The assay mixture was then separated from the beads and analyzed for production of 14 C-phosphopantothenate as described above.
Gel filtration analysis of PanK2. NiNTA-purified human recombinant PanK2-myc-his was applied to a Superose 6 column (Amersham Biosciences) equilibrated in running buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10 mM NaF, 1.5 mM DTT, and PI mixture). Proteins were resolved at a flow rate of 0.4 ml/min. Fractions were collected, and levels of PanK2 were analyzed quantitatively by SDS-PAGE and Western blot using PanK2 549 and 125 I-labeled protein A detection of rabbit primary antibody.
Pulse-chase experiments. QBI 293 cell lines were plated at 3 ϫ 10 5 cells per well in six-well plates and grown to confluence over 3-4 d. Cells were starved for 30 min in 1 ml/well DMEM minus methionine and cysteine containing 10% dialyzed FBS. Cells were then pulse-labeled for 30 min in 1 ml/well of the above medium containing 250 Ci/ml 35 S-labeled methionine and cysteine ( 35 S Express Tag, 14 mCi/ml; Amersham Biosciences). At the end of the 30 min labeling period, the labeling medium was replaced with DMEM and 10% FBS growth medium, and cultures were incubated for additional time periods as indicated. At each time point, cells were washed once in cold PBS, lysed in 0.4 ml/well RIPA buffer containing O-phenanthroline, PI mixture, and PMSF, and immediately frozen on dry ice. Extracts were sonicated and centrifuged at 16,000 ϫ g for 10 min, and the supernatants (200 l) were analyzed by immunoprecipitation with PanK2 549.
Immunoprecipitation. Extracts were preincubated with protein ASepharose beads (Amersham Biosciences), and the beads were removed by centrifugation. Extracts were then incubated for 1.5 h at 4°C with PanK2 549 (0.5 l of antibody per 200 l of extract). Protein A beads (10 l) were added, and samples were incubated with rotation for 1.5 h at 4°C. Beads were pelleted by centrifugation at 2000 ϫ g and washed three times by resuspension in 400 l of RIPA buffer, rotation at 4°C for 10 min, and repeat centrifugation. Bound PanK2 protein was released from the beads by boiling in 15 l of 1ϫ SDS sample buffer and resolved in a 10% SDS polyacrylamide gel. Gels were dried and exposed to a PhosphorImager plate (Molecular Dynamics, Sunnyvale, CA). Quantitation of individual PanK2 isoforms at each time point was performed using Imagequant software (Amersham Biosciences). Half-lives of PanK2 isoforms were estimated by fitting a one-phase exponential decay curve to the data by nonlinear regression using Prism 4 software (GraphPad, San Diego, CA).
Results

PanK2 is localized to neuronal mitochondria in human brain
We developed a panel of both monoclonal and polyclonal antibodies specific for human PanK2 protein. As shown in Figure 1 , polyclonal antibodies raised to two distinct PanK2 peptides and a monoclonal antibody raised against recombinant human PanK2 protein all recognize a 48 kDa protein in Western blots of human postmortem brain extracts (Fig. 1 A) . We used these antibodies to characterize cellular and subcellular patterns of PanK2 expression in human brain. Immunohistochemistry performed with each of the three antibodies generated similar staining patterns in postmortem brain sections. We observed punctate staining of neuronal cell bodies and proximal dendrites throughout the brain. Intensity of staining varied among different neuronal populations but was most prominent in neurons of the cortex, globus pallidus, nucleus basalis of Meynert, and pontine nuclei ( Fig.  1 B-I ). Immunoelectron microscopy demonstrated localization of PanK2 to mitochondria of cortical and globus pallidus neurons in postmortem human brain (Fig. 1 J-M ) .
Multiple PanK2 isoforms observed in brain and transfected cells
The 48 kDa band observed in Western blots was significantly smaller than predicted based on a transcript previously identified in human brain in which initiation of translation from the most 5Ј ATG codon would generate a 63 kDa protein (Hortnagel et al., 2003) . Computer analysis by the MITOPROT algorithm (Claros and Vincens, 1996) predicts proteolytic cleavage of the 4 kDa mitochondrial targeting sequence to yield a 59 kDa protein after targeting to the mitochondria. Alternatively, an ϳ48 kDa protein can be predicted after initiation from a CTG codon 300 bp downstream from the ATG codon (Zhou et al., 2001) . Using reversetranscribed human brain RNA, we were able to PCR amplify the same fulllength PanK2 transcript identified by Hortnagel et al. (2003) , encoding the predicted 63 kDa PanK2 protein when translation is initiated at the first ATG. To characterize the localization and proteolytic processing of protein encoded by this transcript, we generated stably transfected human 293 cells with an expression vector containing the PanK2 coding sequence beginning with the ATG start site. Immunofluorescence staining demonstrated efficient targeting of the expressed protein to the mitochondria based on precise colocalization with mitotracker red fluorescent dye (Fig. 2 A-C) .
Western blot analysis of stably transfected cell extracts revealed an unexpected combination of 59 and 48 kDa protein species (Fig. 2 D) . The 48 kDa protein was ϳ10-fold more abundant than the 59 kDa species. On longer exposures of ECL Western blots, a less abundant 63 kDa band was detected in stably transfected cells (data not shown) (Fig. 2 E) . The 48 kDa isoform in 293 cells was identical in size to the 48 kDa isoform present in brain extracts (Fig. 2 E) . Transient transfection of PanK2 expression vectors, in which the level of protein production per cell was significantly higher, generated a combination of 63 and 48 kDa proteins (Fig. 2 D) .
Mitochondrial PanK2 catalyzes the phosphorylation of pantothenate
After subcellular fractionation of transfected 293 cells by differential centrifugation, PanK2-immunoreactive bands were found predominantly in the mitochondrial fraction (Fig. 2 F) . We used an in vitro enzymatic assay to determine whether PanK2 protein expressed in 293 cells contained pantothenate kinase enzymatic activity. Incubation of extracts in the presence of 14 C-labeled pantothenate and ATP was followed by ion exchange separation of phosphopantothenate product from pantothenate substrate. As shown in Figure 2 F, although extracts of vector-transfected cells contained a detectable amount of catalytic activity, extracts of PanK2-transfected 293 cells possessed significantly higher pantothenate kinase enzymatic activity. Furthermore, the pantothenate kinase enzymatic activity was found predominantly in mitochondrial extracts of PanK2-transfected cells with a distribution nearly identical to that of PanK2 protein in Western blots.
Three PanK2 isoforms produced by sequential proteolytic cleavage
We hypothesized that the three different PanK2 isoforms might be generated by proteolytic processing of a 63 kDa protein translated from the 5Ј ATG initiation site, rather than by initiation of translation at the predicted alternate CTG site in addition to the 5ЈATG. To distinguish between these two possibilities, a pulsechase experiment was performed, in which newly synthesized PanK2 was pulse-labeled with 35 S-methionine and monitored by immunoprecipitation and SDS-PAGE at multiple time points over 24 h during the chase period. Consistent with the proteolytic processing hypothesis, this experiment revealed a clear temporal relationship between the three isoforms, which we have labeled PanK2 precursor (PanK2 p ), PanK2 i , and PanK2 m (Fig. 3) . The 63 kDa PanK2 p is the first species to be detected during the pulse-labeling period, and its levels rapidly decline during the chase period. Initial synthesis of a 52 kDa protein predicted to originate from the CTG start site was not observed. PanK2 i appears next during the pulse, and its levels continue to increase during the chase, as PanK2 p declines. PanK2 m levels rise well into the chase period as the levels of Pank2 i decline. Furthermore, PanK2 m appears to be very longlived. Once its peak is reached, it declines by only 50% over the following 15 h period, suggesting a half-life of 30 h. A band of lower molecular weight than PanK2 m was also detected with a temporal profile parallel to PanK2 m ; however, this band appeared to be less abundant in Western blots of rapidly prepared cell extracts, suggesting that it may be a degradative product generated during cell extraction and immunoprecipitation.
Identification of PanK2 cleavage sites implicates the mitochondrial processing peptidase N-terminal amino acid sequence was obtained from purified PanK2 i and PanK2 m to define the cleavage sites for PanK2 proteolytic processing. Sequencing results revealed cleavage between residues 31 and 32 to generate PanK2 i and cleavage between 140 and 141 to generate PanK2 m (Fig. 4) . Both cleavage sites fit consensus sequences for cleavage by the mitochondrial processing peptidase (MPP) (Gakh et al., 2002) . The first cleavage occurs two amino acids downstream of an arginine residue (R-2 motif), and the second cleavage occurs three amino acids downstream of an arginine residue (R-3 motif). PanK2 m contains 82 amino acids preceding the 350 amino acid core catalytic domain that is highly conserved among PanK1, PanK2, and PanK3 (Fig. 4 D) . By analogy with PanK1, this unique N-terminal domain of PanK2 may function to regulate the catalytic activity of the protein (Rock et al., 2002) .
PanK2 i and PanK2 m were chromatographically separated on a cation exchange column to evaluate the catalytic activity of each isoform in an in vitro enzymatic assay. As shown in Figure 5 , PanK2 i and PanK2 m possessed comparable catalytic activity, suggesting that the second proteolytic processing step is not necessary to generate A, Cells were harvested at the indicated times after the initiation of labeling and analyzed by immunoprecipitation with PanK2 549 followed by SDS-PAGE. Migration of molecular weight markers is indicated on the left. The positions of the three major PanK2 isoforms are indicated on the right (note the 3 kDa upward shift in molecular weight caused by myc-his tag). A 40 kDa band was inconsistently observed and may arise from proteolysis of the mature isoform during sample processing. B, Quantitation of relative amounts of labeled isoforms at each time point demonstrates the temporal relationship of PanK2 isoforms. PanK2 p is the first isoform to appear during the labeling period, and its levels rapidly decline during the chase period as levels of PanK2 i rise. The PanK2 m isoform rises in a delayed manner corresponding to the decline of the PanK2 intermediate isoform. Similar results were obtained using multiple clonal lines in more than three separate experiments with both native and myc-his-tagged human PanK2. a catalytically active protein. Steadystate levels of PanK2 p were not high enough to allow evaluation of its catalytic activity. Bacterial pantothenate kinase protein, which possesses Ͻ3% sequence homology to PanK2 is a dimer, and displays cooperative binding of 2 ATP molecules per dimer (Song and Jackowski, 1994) . Fractionation of mychis-tagged PanK2 m by size-exclusion chromatography revealed a relative molecular weight of 109 kDa, double the calculated monomeric size of 51 kDa, indicating that PanK2 exists as a dimer under native conditions (Fig. 5C,D) .
Acyl CoAs inhibit PanK2 catalytic activity
In both prokaryotic and eukaryotic systems, pantothenate kinase activity has been shown to be rate limiting in the synthesis of CoA (Jackowski and Rock, 1981; Rock et al., 2000) . Because initial enzymatic reactions are often subject to feedback regulation in biosynthetic pathways, we examined the regulation of PanK2 catalytic activity by CoA and CoA esters using purified recombinant PanK2 (Fig. 5E ). PanK2 catalytic activity was significantly decreased in the presence of CoA with an IC 50 value of ϳ50 M. This effect of CoA appeared to be specific, because there was no significant effect of dephospho-CoA, the penultimate intermediate in CoA biosynthesis. However, the effect of CoA on PanK2 catalytic activity was modest compared with CoA esters such as palmitoyl CoA (Fig. 5E ), acetyl CoA, and malonyl CoA (data not shown). Each of these species of acyl CoA inhibited PanK2 catalytic activity at a much lower concentration with an IC 50 value of ϳ1 M. Furthermore, the maximum inhibitory effect was dramatic. PanK2 catalytic activity is reduced to 0.5% of basal activity in the presence of 20 M palmitoyl CoA.
Disease-associated mutations alter processing, stability, and catalytic activity of PanK2
More than 50 different mutations in the PanK2 gene have been identified in patients with NBIA (Hayflick et al., 2003) . Although several mutations result in a frameshift or premature stop codon early in the PanK2 coding sequence, Ͼ30 mutations resulting in single amino acid substitutions have been reported. We evaluated the effect of several disease-associated point mutations on the mitochondrial localization, proteolytic processing, and catalytic activity of PanK2 [amino acid numbers used to designate point mutations are increased by the 110 amino acids preceding the predicted CTG start site used for numbering of amino acids in Hayflick et al. (2003) ]. Proteins containing the E134G, G219V, T234A, S471N, G521R, and T528M mutations were all efficiently targeted to mitochondria, as assessed by colocalization of immunofluorescent staining with mitotracker red (shown for G521R in Fig. 6 A-C) .
We observed altered steady-state levels of the mature and intermediate isoforms for G521R mutant protein (Fig. 6 D) . In both transient and stable transfection of 293 cells, levels of G521R PanK2 were significantly lower than WT PanK2. Furthermore, the ratio of intermediate to mature G521R PanK2 was ϳ1:1 rather than the 1:10 ratio typically observed for WT PanK2. We compared the proteolytic processing and stability for G521R and WT protein in pulse-chase experiments (Fig. 6 E,F ) . For G521R PanK2, we observed marked instability of PanK2 i , reduced processing to PanK2 m , and instability of PanK2 m . The half-life of G521R PanK2 i was estimated to be 27 min, compared with 156 min for WT PanK2 i (Fig. 6 F) . In contrast to the delayed rise in WT PanK2 m during the chase period, levels of G521R PanK2 m declined, suggesting that cleavage of the intermediate isoform is impaired. Quantitative analysis revealed that, as a percentage of total PanK2 protein (all three isoforms) present at the end of the 30 min pulse-labeling period, the amount of mature PanK2 produced after 360 min was Ͻ2% of that produced in parallel pulse-chase experiments with WT PanK2 (Fig. 6F ) (compare Fig. 3B, 6E) . We compared specific enzymatic activity of several mutant PanK2 proteins to WT PanK2 protein in transient transfection experiments. Expression levels of WT and mutant PanK2 proteins in extracts of transiently transfected cells were determined by quantitative Western blots with detection by 125 I-labeled sec- The position of NBIA-associated point mutations is indicated with amino acid numbers corresponding to the ATG start site rather than the CTG start site (Hayflick et al., 2003) .
ondary antibodies. Analysis by in vitro enzymatic assay of normalized concentrations of WT and mutant PanK2 proteins revealed that three point mutations (G219V, S471N, and G521R) resulted in a Ն90% reduction in enzymatic activity (Fig. 7) . However, the specific activities of PanK2 containing the E134G, T234A, and T528M mutations did not differ significantly from WT in these experiments, and additional in vitro experiments using purified recombinant protein confirm no loss in activities of these mutants. We were also unable to detect significant differences in the sensitivity of these three mutant proteins to inhibition by acetyl CoA (data not shown). Quantitative analyses of pulse-chase experiments also revealed no alterations in processing or stability of these three mutant proteins (data not shown).
Discussion
The identification of mutations in the PanK2 gene offers a unique opportunity to investigate mechanisms of NBIA pathogenesis. Because NBIA shares several pathological features with other more common neurodegenerative diseases, such as inclusion formation and iron accumulation, it may also share mechanisms of pathogenesis. The consequences of the many NBIA-associated point mutations on the function of PanK2 protein has not been investigated. Furthermore, although mitochondrial targeting of Pank2 fusion proteins has been demonstrated in cell culture experiments (Hortnagel et al., 2003) , the cellular and subcellular localization of PanK2 in human brain has not been examined. Our results demonstrate that PanK2 protein is expressed in the mitochondria of neurons in those brain regions that are impaired in NBIA. They also demonstrate that some, but not all, disease-associated mutations alter PanK2 function by disrupting maturation and stability of the mitochondrially targeted protein and by disrupting catalytic activity. Interestingly, we observed that several point mutations do not alter PanK2 catalytic activity as measured in vitro. This suggests that there may be additional mechanisms by which mutations can alter PanK2 function in the mitochondria. Because the T234A and T528M mutations have been most frequently associated with later onset and more slowly progressive disease (Zhou et al., 2001; Hayflick et al., 2003) , these mutations might alter PanK2 function by a mechanism that becomes significant only in the context of environmental factors or increasing age.
The sequential proteolytic processing observed after targeting of PanK2 to the mitochondria is unusual, particularly if the MPP is responsible for both cleavage steps as predicted by the identification of the cleavage sites. Both the mitochondrial intermediate peptidase (MIP) and the mitochondrial inner membrane peptidase (IMP) can process specific subsets of proteins after initial cleavage by MPP. IMP cleavage can occur for nucleus-encoded proteins targeted to the inner membrane. MIP is responsible for cleavage of an N-terminal octapeptide after initial cleavage of a targeting sequence by MPP. However, neither of these peptidases appears to be involved in PanK2 cleavage based on the position and sequence of the cleavage site for PanK2 i .
Sequential cleavage by MPP has been observed for one other mammalian protein, human frataxin, which is mutated in the neurodegenerative disease Friedreich's ataxia (Branda et al., 1999) . As we have observed for PanK2, the second cleavage of frataxin occurs more slowly than the initial cleavage and limits the rate of mature frataxin production (Cavadini et al., 2000) . Furthermore, an interaction between the ␤-MPP subunit and the precursor form of frataxin has been observed in a yeast twohybrid screen (Koutnikova et al., 1998) . Frataxin is involved in the maturation of iron-sulfur cluster proteins and mitochondrial metabolism (Pandolfo, 2002) , an interesting link to the iron accumulation that occurs with PanK2 mutations.
Although PanK1, PanK3, and PanK4 also appear to be expressed in brain by Northern blot analysis (Zhou et al., 2001 ), they do not possess mitochondrial-targeting sequences. By virtue of its mitochondrial localization, PanK2 may function to regulate the biosynthesis of CoA and ultimately lipid metabolism according to specific mitochondrial metabolic needs. PanK1 enzymatic activity is tightly regulated by levels of CoA and CoA esters in vitro, and the response to CoA differs between two PanK1 protein isoforms generated by alternate mRNA splicing (Rock et al., 2000 (Rock et al., , 2002 . Furthermore, as for bacterial PanK, mammalian PanK1 activity limits the rate of CoA synthesis in cell lines, suggesting that this first in a series of five enzymatic steps is a point of regulation at which CoA synthesis is titrated to the metabolic needs of the cell. The ability to assess PanK2 enzymatic activity in vitro may allow investigation of regulatory mechanisms unique to PanK2, perhaps providing further insight into mechanisms by which this enzyme might regulate CoA synthesis within the mitochondrial environment.
The mitochondrial localization of PanK2 and the regulation of PanK2 activity by species of acyl CoA may have potential relevance to a separate pathway for fatty acid synthesis within the mitochondria. The fatty acid synthase complex uses acetyl and malonyl CoA in addition to acyl carrier protein (ACP), which requires a CoAderived phosphopantetheine group covalently linked to a serine residue for its function as an acyl carrier. Although the cytosolic ACP and fatty acid synthetase complex have been characterized as the major proteins involved in fatty acid synthesis, a mitochondrial ACP protein distinct from cytosolic ACP has also been identified and shown to contain a phosphopantetheine prosthetic group (Sackmann et al., 1991; Zhang et al., 2003) . The precise role of a separate mitochondrial pathway for fatty acid synthesis is not yet clear, but there is evidence in fungal systems that it may be essential for maintenance of phospholipids of the mitochondrial membranes (Schneider et al., 1995 (Schneider et al., , 1997 . Alternatively, other fatty acyl CoA derivatives may be important products of this pathway.
Our results suggest that alterations in mitochondrial metabolism and perhaps specific pathways of mitochondrial lipid metabolism may underlie the neurodegenerative process in NBIA. The link between PanK2 mutations and iron accumulation in specific brain regions remains unclear. Mitochondria are the predominant consumers of imported cellular iron, where it is incorporated into heme groups and ironsulfur clusters, which are intrinsic to the activity of numerous mitochondrial enzymes, including the respiratory chain complexes. It is possible that products of mitochondrial lipid synthesis are required for iron metabolism or that altered levels of specific lipid species may directly mediate regulation of iron transport proteins. Generation of cellular and animal models of PanK2 loss of function may allow further investigation of altered iron transport in NBIA.
Mitochondrial DNA mutations are responsible for a number of degenerative neurological conditions, but neuropathological studies of these diseases have not revealed iron accumulation or inclusion formation similar to NBIA (Betts et al., 2004) . Alterations in iron metabolism do occur in other hereditary neurodegenerative diseases, such as aceruloplaminemia and Friedreich's ataxia, but with anatomic patterns of iron accumulation and neurodegeneration that are distinct from NBIA (Roy and Andrews, 2001; Kaneko et al., 2002) . Thus, distinct neuronal populations may be selectively vulnerable to disruption of specific metabolic processes.
Deficits in mitochondrial complex I have been detected in postmortem brain and other tissues in Parkinson's disease (Bindoff et al., 1989; Parker et al., 1989; Schapira et al., 1990; Shoffner et al., 1991; Mann et al., 1992; Cardellach et al., 1993) . Furthermore, partial inhibition of complex I with rotenone causes neurodegeneration in rats that includes the substantia nigra and other regions (Betarbet et al., 2000; Hoglinger et al., 2003) . Recently, mutations in PTEN-induced kinase 1, a mitochondrially localized serinethreonine protein kinase, were identified in a rare familial parkinsonian syndrome (Valente et al., 2004) .
Specific links between the mitochondrial defects of these various diseases remain undefined. However, further investiga- tion of the neurodegenerative mechanisms in NBIA and other disorders may reveal common metabolic alterations that lead to common pathological features such as protein fibrillization, oxidative stress, and iron accumulation.
